BioWorld looks at translational medicine, including: See in 3D; Tolerizing DCs are made, not born; GOF, LOF mutations take different paths to same result; NEFA’s nefarious role in pancreatitis; Comprehensive look identifies insulin autoantigens.

Like Berlin patient Timothy Ray Brown before him, London patient Adam Castillejo, whose case was top story of the 2019 Conference on Retroviruses and Opportunistic Infections (CROI), energized the HIV cure research field by his sheer existence. Curing HIV, Pablo Tebas told the audience at a themed discussion on curative strategies, “has been considered [for] a long time the holy grail.”

CYBERSPACE – Continuing improvements in HIV treatment and progress toward a cure notwithstanding, an effective vaccine will be necessary to gain the upper hand in the decades-long fight against the pandemic.

In the Marvel Comic Universe, Venom is a superhero who started life as a supervillain and Spiderman foe. In the biopharma universe, scorpion venom is undergoing the same fate transformation, as separate papers this week reported new ways to use scorpion venom in two major therapeutic targeting challenges.

BioWorld looks at translational medicine, including: Serine improves memory in Alzheimer’s mouse model; From junk to noncoding to coding; Keeping stem cells quiescent enables greater ultimate potency; Female, male fat tissue flight inflammation differently; BioPROTACs cut out middleman, and small molecule; ‘Gut bug’ has intratumoral effects; Decoy exosomes fight bacterial toxin; Unexpected mechanism, combination possibilities for CDK 4/6 inhibitors; In SIV infection, gut integrity is retained, not repaired.

An experimental gene editing therapy for an inherited form of blindness has become the first in vivo CRISPR medicine to be administered to patients, according to Editas Medicine Inc. and its partner, Allergan plc, which licensed the candidate in 2018.

Sadly, a major part of the answer to why drugs are so expensive appears to be “because they can be.” But the high cost of drugs has also spurred a number of attempts to find medicines that are innovative but remain affordable. Drug repurposing, or using a drug that has been developed for one ailment to treat a different one, is one such strategy.

Lowering levels of tau protein improved multiple symptoms of autism spectrum disorders (ASD) in two different mouse models of the disease, both of which are driven by hyperactivity of the mTOR PI3 kinase pathway.

BioWorld looks at translational medicine, including: Finding the next pandemic threat early on; Microglial fresh start helps heal brain trauma; Finding the silent majority; Anatomy study reveals schizophrenia subtypes; Increasing immune activity improves autoimmunity; How cancer cells hibernate…; …And who makes their bed; Blocking trash trashes MSI-hi tumors; New splicing factor implicated in muscular dystrophy.

Everything’s good for something. Including, it turns out, 5’ untranslated trinucleotide repeats. In the Feb. 17, 2020, issue of Nature Neuroscience, researchers have demonstrated a role for such repeats in controlling protein levels of fragile X mental retardation protein (FMRP).